|
|
|
|
| Now available on demand! Choosing the right CDMO for antibody development is crucial. The wrong partner can lead to delays and quality issues, while the right one can streamline development and improve commercialization success. Join Outsourced Pharma's expert panel on CDMO selection for biologic drug developers, where experts will discuss qualification processes, partnership management, team and facility compatibility, and how to leverage your CDMO's strategic expertise. |
|
|
|
|
By Matthew Pillar, Editor, Bioprocess Online
| Complex protein therapeutic innovators are often orchestrating the work of three, four, or more outsourced manufacturing partners at once. Hear from ADC and a CDMO process development specialist. |
|
|
|
By Mei-Chun Yang, CEO, GlycoNex | Outsourcing antibody-drug conjugate manufacturing is the status quo. This executive explains why her company chooses to do it themselves for reasons including quality control and cost management. |
|
|
|
|
|
|
|
|
|
|
|
|
